ArticleRMD open2026

Cost-effectiveness of secondary prevention of rheumatoid arthritis with methotrexate in the Netherlands: differences between developing ACPA-positive and ACPA-negative disease.

Elise van Mulligen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.